Microdosing
Microdosing involves the regular consumption of sub-hallucinogenic doses of psychedelics, primarily for cognitive enhancement and emotional wellbeing. Although popularised through anecdotal reports, rigorous scientific evidence on its effects is still limited, pointing to a critical need for further research in this emerging field.
What is Microdosing?
Microdosing refers to the use of low doses of psychedelic substances, typically below the threshold of perceptual effects, administered over multiple sessions with the intention of enhancing cognitive and emotional processes.
The most commonly reported substances used in microdosing are LSD and psilocybin, which are often taken on a specific schedule, such as one day on followed by two days off.
Anecdotal reports suggest benefits such as improved mental wellbeing, increased focus, and enhanced creativity; however, these claims require substantiation through scientifically rigorous methodologies.
Lack of robust clinical trials has resulted in microdosing being predominantly studied through self-reported measures, such as surveys, raising concerns about the reliability of the findings.
Current Treatments
Standard treatments for conditions like ADHD and anxiety currently include pharmacological approaches such as stimulants and SSRIs, along with behavioural therapies. These interventions, while effective, may not work for all individuals and can present side effects.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Microdosing.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| LSD Evidence primarily derived from self-reported surveys, with few clinical studies completed. | Medium | Moderate | Inconsistent |
| Psilocybin Similar to LSD, relies on self-reported outcomes with limited controlled studies thus far. | Medium | Moderate | Inconsistent |
LSD and Microdosing
LSD is known for its profound psychological effects, even at microdose levels. Users report enhanced cognitive flexibility, improved mood, and heightened creativity, although scientific validation of these claims is sparse. Preliminary findings suggest microdosing LSD may facilitate neural plasticity, which could have implications for cognitive enhancement in daily activities.
Psilocybin and Microdosing
Microdoses of psilocybin may assist in emotional regulation and cognitive improvement, according to anecdotal accounts. Early observational studies indicate that psilocybin could help alleviate symptoms related to anxiety and depression, potentially shifting the neurochemical balance towards a more positive emotional state, yet the need for controlled trials remains critical to ascertain these effects.
Key Insights
- 1
Microdosing has gained popularity, particularly among young professionals, for perceived benefits in mental health and cognitive performance.
- 2
Self-reported data indicates that microdosing may be associated with lower prevalence of substance use disorders and anxiety among users.
- 3
Preliminary studies suggest microdosing may significantly impact symptoms of ADHD, offering a potential alternative to conventional medications.
- 4
Current research highlights the need for controlled clinical trials to validate the anecdotal benefits and safety of microdosing practices.
- 5
The placebo effect may play a significant role in reported outcomes of microdosing, necessitating further investigation.
Industrial Landscape
Key players in the microdosing space include Woke Pharmaceuticals, which is developing novel psychedelic compounds, and MindBio Therapeutics, conducting clinical research on microdosing for various mental health conditions. Notable researchers like Vince Polito from Macquarie University are also contributing to the scientific exploration of microdosing effects.
Quick Indicators
\"Ongoing clinical evaluations are investigating Microdosing as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Microdosing.